Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$7.25 USD
-0.47 (-6.09%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $7.23 -0.02 (-0.28%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ACRV 7.25 -0.47(-6.09%)
Will ACRV be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ACRV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACRV
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Repligen (RGEN) Promotes CCO, Shares Fall on Leadership Change
ACRV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
Ultragenyx (RARE) Posts New Data From Bone Disease Study
SAGE's Huntington's Disease Study Meets Primary Endpoint
Other News for ACRV
Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?
Optimistic Buy Rating for Acrivon Therapeutics Based on Promising ACR-2316 Prospects and Innovative AP3 Platform
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
Acrivon Therapeutics: A Buy Rating on Strong Clinical and Financial Prospects
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024